Serial measurement of high-sensitivity C-reactive protein following an acute coronary syndrome may help flag patients at elevated risk for morbidity and mortality, finds a secondary analysis of the VISTA-16 trial.
A pending USPSTF recommendation on nontraditional cardiac risk factors for asymptomatic adults gets it right for two of three factors addressed, contends Dr. Steve Nissen.
The recent landmark trial conclusively proved the inflammatory hypothesis of atherothrombosis. But it did a good deal more. Dr. Steven Nissen explains.